Human cytomegalovirus Fcγ binding proteins gp34 and gp68 antagonize Fcγ receptors I, II and III
Autor: | Mirko Trilling, Vu Thuy Khanh Le, Manuela Fiedler, Henrike Reinhard, Katja Hunold, Albert Zimmermann, David C. Johnson, Hartmut Hengel, Enver Aliyev, Eva Mercé-Maldonado, Eugenia Corrales-Aguilar, Katrin Ehrhardt |
---|---|
Rok vydání: | 2013 |
Předmět: |
Human cytomegalovirus
viruses Medizin Cytomegalovirus Herpesvirus 1 Human Virus Replication Immunoglobulin G Chlorocebus aethiops lcsh:QH301-705.5 Cells Cultured CD64 Membrane Glycoproteins biology Viral Immune Evasion virus diseases Host-Pathogen Interactions Protein Binding Research Article lcsh:Immunologic diseases. Allergy medicine.drug_class Immunology CD16 Monoclonal antibody Microbiology Viral Proteins Immune system Antigen Virology Genetics medicine Animals Humans Molecular Biology Glycoproteins Receptors IgG Immunity Biology and Life Sciences biochemical phenomena metabolism and nutrition medicine.disease Immunoglobulin Fc Fragments HEK293 Cells lcsh:Biology (General) Polyclonal antibodies Humoral Immunity biology.protein Parasitology lcsh:RC581-607 Carrier Proteins |
Zdroj: | PLoS Pathogens PLoS Pathogens, Vol 10, Iss 5, p e1004131 (2014) PLOS Pathogens, vol. 10(5), art. e1004131 Kérwá Universidad de Costa Rica instacron:UCR |
ISSN: | 1553-7374 |
Popis: | Human cytomegalovirus (HCMV) establishes lifelong infection with recurrent episodes of virus production and shedding despite the presence of adaptive immunological memory responses including HCMV immune immunoglobulin G (IgG). Very little is known how HCMV evades from humoral and cellular IgG-dependent immune responses, the latter being executed by cells expressing surface receptors for the Fc domain of IgG (FcγRs). Remarkably, HCMV expresses the RL11-encoded gp34 and UL119-118-encoded gp68 type I transmembrane glycoproteins which bind Fcγ with nanomolar affinity. Using a newly developed FcγR activation assay, we tested if the HCMV-encoded Fcγ binding proteins (HCMV FcγRs) interfere with individual host FcγRs. In absence of gp34 or/and gp68, HCMV elicited a much stronger activation of FcγRIIIA/CD16, FcγRIIA/CD32A and FcγRI/CD64 by polyclonal HCMV-immune IgG as compared to wildtype HCMV. gp34 and gp68 co-expression culminates in the late phase of HCMV replication coinciding with the emergence of surface HCMV antigens triggering FcγRIII/CD16 responses by polyclonal HCMV-immune IgG. The gp34- and gp68-dependent inhibition of HCMV immune IgG was fully reproduced when testing the activation of primary human NK cells. Their broad antagonistic function towards FcγRIIIA, FcγRIIA and FcγRI activation was also recapitulated in a gain-of-function approach based on humanized monoclonal antibodies (trastuzumab, rituximab) and isotypes of different IgG subclasses. Surface immune-precipitation showed that both HCMV-encoded Fcγ binding proteins have the capacity to bind trastuzumab antibody-HER2 antigen complexes demonstrating simultaneous linkage of immune IgG with antigen and the HCMV inhibitors on the plasma membrane. Our studies reveal a novel strategy by which viral FcγRs can compete for immune complexes against various Fc receptors on immune cells, dampening their activation and antiviral immunity. Author Summary Herpes viruses persist lifelong continuously alternating between latency and virus production and transmission. The latter events occur despite the presence of immune IgG antibodies. IgG acts by neutralization of virions and activation of immune cells bearing one or more surface receptors, called FcγRs, recognizing the constant Fc domain of IgG. Activating FcγRs induce a wide range of immune responses, including antibody dependent cellular cytotoxicity (ADCC) of virus-infected cells by natural killer (NK) cells, cytokine secretion and the uptake of immune complexes to enhance antigen presentation to T cells. We demonstrate that the HCMV glycoproteins RL11/gp34 and UL119-118/gp68 block IgG-mediated activation of FcγRs. A novel reporter cell-based assay was used to test FcγRs individually and assess their relative susceptibility to each antagonist. This approach revealed that gp34 and gp68 block triggering of activating FcγRs, i.e. FcγRI (CD64), FcγRII (CD32A) and FcγRIII (CD16). Co-immunoprecipitation showed the formation of ternary complexes containing IgG, IgG-bound antigen and the viral antagonists on the cell surface. Assigning the redundant abilities of HCMV to hinder IgG effector responses to the viral Fc binding proteins, we discuss gp34 and gp68 as potential culprits which might contribute to the limited efficacy of therapeutic IgG against HCMV. |
Databáze: | OpenAIRE |
Externí odkaz: |